Treatment of Aspergillosis

Area of Science:

• Mycology
• Infectious Diseases
• Clinical Medicine

Background:

• Infections caused by Aspergillus species lead to significant morbidity and mortality.
• While antifungal prophylaxis reduces invasive aspergillosis (IA) in high-risk patients, breakthrough cases occur.
• IA is increasingly seen in non-neutropenic groups, presenting atypical symptoms and diagnostic challenges.

Purpose of the Study:

• To review current treatment strategies for invasive aspergillosis (IA).
• To highlight diagnostic challenges associated with IA, particularly in non-neutropenic patients.
• To discuss treatment options for chronic pulmonary aspergillosis (CPA).

Main Methods:

• Review of current medical literature and treatment guidelines for aspergillosis.
• Analysis of diagnostic limitations for IA.
• Evaluation of therapeutic recommendations for IA and CPA.

Main Results:

• Breakthrough IA remains difficult to diagnose due to low mycological test sensitivity.
• Atypical presentations complicate IA diagnosis in non-neutropenic patients.
• Voriconazole and/or isavuconazole are recommended for primary IA treatment; liposomal amphotericin B is an alternative.
• Posaconazole and echinocandins are typically used for salvage therapy.
• Long-term itraconazole or voriconazole are standard for chronic pulmonary aspergillosis (CPA).

Conclusions:

• Early and targeted systemic antifungal treatment is vital for successful outcomes in immunocompromised patients with IA.
• Diagnostic challenges necessitate careful clinical evaluation and consideration of emerging diagnostic tools.
• Current guidelines provide a framework for IA management, with specific recommendations for primary, alternative, and salvage therapies.
• Treatment options for CPA require further investigation, with current standards focusing on long-term azole therapy.